| Sep 13 |
Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Sep 11 |
Allarity Therapeutics executes 1-for-30 reverse stock split
|
| Sep 11 |
Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)
|
| Aug 30 |
Allarity Therapeutics files to sell 18.53M shares of common stock for holders
|
| Jul 26 |
Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
|
| Jul 24 |
Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares
|
| Jul 24 |
Why Enphase Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
|
| Jul 22 |
Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives
|
| Jun 27 |
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
|
| Jun 25 |
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
|
